C-reactive protein, body mass index, and diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 9, 2010, Pages 4458-4463

  Lim, Laurence Shen ^a   Shyong Tai, E ^b   Mitchell, Paul ^c   Wang, Jie Jin ^c,d   Tay, Wan Ting ^a   Lamoureux, Ecosse ^a,d   Wong, Tien Yin ^a,d,e  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; AGE; AGED; ARTICLE; ASIAN; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALAY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX; ETHNOLOGY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PREVALENCE; RISK FACTOR; SINGAPORE; STATISTICS;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGAPORE;

EID: 77957339847     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4939     Document Type: Article

References (60)

1. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008;115:1869-1875.
2. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902-916.
3. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58.
4. Fong DS, Segal PP, Myers F, Ferris FL, Hubbard LD, Davis MD. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1997;115:873-877.
5. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology. 1992;99:58-62.
6. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
7. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563.
8. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes. 1988;37: 878-884.
9. Varma R, Macias GL, Torres M, Klein R, Pena FY, Azen SP. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology. 2007;114:1332-1340.
10. van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300-1306.
11. Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 2007;24:969-976.
12. Lambert J, Aarsen M, Donker AJ, Stehouwer CD. Endotheliumdependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:705-711.
13. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
14. Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilation of retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci. 2008;49:2053-2060.
15. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005;2:29-36.
16. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
17. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094-2099.
18. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
19. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes. 2000;49:485-491.
20. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:3071-3078.
21. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219-4225.
22. Jager A, van Hinsbergh VW, Kostense PJ, et al. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2002;22:593-598.
23. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157-1165.
24. Le DS, Miles R, Savage PJ, et al. The association of plasma fibrinogen concentration with diabetic microvascular complications in young adults with early-onset of type 2 diabetes. Diabetes Res Clin Pract. 2008;82:317-323.
25. Nguyen TT, Alibrahim E, Amirul IF, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32: 1704-1709.
26. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127:1175-1182.
27. Dowse GK, Humphrey AR, Collins VR, et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol. 1998;147:448-457.
28. Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol. 2007;52:180-195.
29. Chaturvedi N, Fuller JH. Mortality risk by body weight and weight change in people with NIDDM. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetes Care. 1995;18:766-774.
30. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527-532.
31. Lee ET, Lee VS, Lu M, Russell D. Development of proliferative retinopathy in NIDDM: a follow-up study of American Indians in Oklahoma. Diabetes. 1992;41:359-367.
32. West KM, Erdreich LJ, Stober JA. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes. 1980;29:501-508.
33. Nilsson SV, Nilsson JE, Frostberg N, Emilsson T. The Kristianstad survey. II. Studies in a representative adult diabetic population with special reference to comparison with an adequate control group. Acta Med Scand Suppl. 1967;469:1-42.
34. Kornerup T. Studies in diabetic retinopathy: an investigation of 1,000 cases of diabetes. Acta Med Scand. 1955;153:81-101.
35. Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1997;157: 650-656.
36. Sharma SK, Mishra HK, Sharma H, et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med. 2008;9:149-156.
37. Tamakoshi K, Yatsuya H, Kondo T, et al. Long-term body weight variability is associated with elevated C-reactive protein independent of current body mass index among Japanese men. Int J Obes Relat Metab Disord. 2003;27:1059-1065.
38. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-2135.
39. Lapice E, Maione S, Patti L, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32:1734-1736.
40. Kao TW, Lu IS, Liao KC, Lai HY, Loh CH, Kuo HK. Associations between body mass index and serum levels of C-reactive protein. S Afr Med J. 2009;99:326-330.
41. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2005;48:370-378.
42. Islam FM, Nguyen TT, Wang JJ, et al. Quantitative retinal vascular calibre changes in diabetes and retinopathy: the Singapore Malay eye study. Eye. 2009;23(8):1719-1724.
43. Foong AW, Saw SM, Loo JL, et al. Rationale and methodology for a population-based study of eye diseases in Malay people: The Singapore Malay eye study (SiMES). Ophthalmic Epidemiol. 2007;14: 25-35.
44. Jeganathan VS, Kawasaki R, Wang JJ, et al. Retinal vascular caliber and age-related macular degeneration: the Singapore Malay Eye Study. Am J Ophthalmol. 2008;146:954-959.
45. Wong TY, Chong EW, Wong WL, et al. Prevalence and causes of visual impairment and blindness in an urban Malay Population: the Singapore Malay Eye Study (SiMES). Arch Ophthalmol. 2008; 126(8):1091-1099.
46. Report of the World Health Organization Consultation on Obesity. Preventing and Managing the Global Epidemic of Obesity. Geneva; WHO; 1997.
47. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006; 141:446-455.
48. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology. 1998;105:406-411.
49. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye. 2007;21: 465-471.
50. Sun C, Liew G, Wang JJ, et al. Retinal vascular caliber, blood pressure, and cardiovascular risk factors in an Asian population: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci. 2008; 49:1784-1790.
51. Su DH, Wong TY, Wong WL, et al. Diabetes, hyperglycemia, and central corneal thickness The Singapore Malay Eye Study. Ophthalmology. 2008;115(6):964-968.e1.
52. Shankar A, Leng C, Chia KS, et al. Association between body mass index and chronic kidney disease in men and women: populationbased study of Malay adults in Singapore. Nephrol Dial Transplant. 2008;23:1910-1918.
53. Xu Y, Whitmer K. C-reactive protein and cardiovascular disease in people with diabetes: high-sensitivity CRP testing can help assess risk for future cardiovascular disease events in this population. Am J Nurs. 2006;106:66-72.
54. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275-1279.
55. Wong TY, Duncan BB, Golden SH, et al. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities Study. Invest Ophthalmol Vis Sci. 2004;45:2949-2954.
56. Boncler M, Watala C. Regulation of cell function by isoforms of C-reactive protein: a comparative analysis. Acta Biochim Pol. 2009;56:17-31.
57. Bello G, Cailotto F, Hanriot D, et al. C-reactive protein (CRP) increases VEGF-A expression in monocytic cells via a PI3-kinase and ERK 1/2 signaling dependent pathway. Atherosclerosis. 2008; 200:286-293.
58. Hanriot D, Bello G, Ropars A, et al. C-reactive protein induces proand anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost. 2008; 99:558-569.
59. Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004;21: 810-817.
60. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147:583-586.